Saliva insulin differentiates between normal and hyperinsulinemic responses in normoglycemic individuals
MONDAY, Aug. 18, 2025 (HealthDay News) — Saliva insulin can differentiate between normal and hyperinsulinemic responses among normoglycemic adults with different body mass index (BMI) classes, according to a study published online May 16 in Applied Physiology, Nutrition, and Metabolism.
Hossein Rafiei, Ph.D., R.D., from St. Louis University, and Jonathan Peter Little, Ph.D., from the University of British Columbia in Vancouver, Canada, characterized saliva insulin responses to a standardized meal tolerance test. Ninety-four healthy normoglycemic adults were recruited and categorized into normal weight (NW; 41 participants), overweight (OW; 23 participants), and obese (OB; 30 participants). Participants consumed a standardized liquid meal after fasting for four or more hours. At fasting, 60 minutes, and 90 minutes post meal, saliva samples and finger prick blood glucose were collected.
The researchers found that at all time points, saliva insulin levels were significantly higher in the OB versus the OW and NW groups. Higher insulin levels were also seen in the OW versus the NW group. Among the groups, there were no significant differences in fasting and post-meal glucose levels. There were strong positive correlations between obesity markers and saliva insulin levels. Preliminary cut-off values for fasting, 60 minutes, and 90 minutes post-meal saliva insulin may differentiate between normal and hyperinsulinemic responses (about 16, 97, and 115 pmol/L, respectively).
“People living with obesity had much higher insulin levels in their saliva than those who were slightly overweight or had lower body weight — even though their blood sugar levels were the same,” Little said in a statement. “This suggests that saliva testing could be a simple, noninvasive way to identify people at risk of type 2 diabetes before symptoms appear.”
One author disclosed ties to relevant organizations.
Abstract/Full Text (subscription or payment may be required)
Vascular Burden in Midlife Linked to Increased Risk for Dementia, Death
GLP-1 Receptor Agonists Tied to Increased Risk for Alopecia
Food-Based Support Aids Type 2 Diabetes Outcomes
Hypoglossal Nerve Stimulation May Offer Long-Term Cardiovascular Benefits in OSA
28 Percent of U.S. Adults With HTN Eligible for Treatment Under New Guidelines
Press-Needle Therapy Shows Potential for Pediatric Allergic Rhinitis
Burden of Myocardial Dysfunction Elevated for Individuals With Psoriasis
2017 to 2022 Saw More Than Doubling in Use of GLP-1 Receptor Agonists